Also known as: type II diabetes
Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction causing hyperglycemia. It is the most common type of diabetes.
BMI normalization was linked to a 48.4% lower hazard of progression to stage 3 type 1 diabetes. A review of 46 studies found African indigenous foods may reduce inflammation in type 2 diabetes.
BBB-crossing antihypertensives tied to lower dementia, mortality risk. Angiotensin II-stimulating drugs linked to lower Alzheimer biomarkers. Calcium channel blockers top-ranked for dementia prevention.
Forecasts show the obesity and diabetes drugs market expanding through 2035 on GLP-1 adoption, Europe's HIFU market reaching USD 65.57B by 2033, and AI precision medicine growing at a 31.3% CAGR.
A study in Diabetologia shows type 2 diabetes in lean Africans is driven by insulin shortage, not insulin resistance, and may require different treatment than standard guidelines. The study analyzed data from over 3,300 African adults and found distinct complication patterns between lean and overweight patients.
A retrospective cohort study of 14,118 matched pairs found tirzepatide associated with lower risks of stroke and death than other GLP-1 receptor agonists in patients with atrial fibrillation and type 2 diabetes. Absolute differences were 2.1 percentage points for stroke and 6.2 for mortality at one year. Randomized trials are needed before recommendations change.
Oral semaglutide cut heavy drinking and cravings in an 8-week AUD trial. The VA is testing semaglutide in the CRAVE trial enrolling more than 600 veterans.
Physician-supervised clinics in Florida and Texas offer semaglutide and tirzepatide weight loss programs. Clinical trials show average weight loss of 15% with semaglutide and about 21% with tirzepatide. All-inclusive monthly plans start at $349.
Recent studies on metformin and age-related macular degeneration report conflicting findings: a JAMA Ophthalmology cohort found no association, while studies in Ophthalmology Retina and BMJ Open Ophthalmology found reduced odds of neovascular and intermediate AMD, respectively. All were observational.
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
New research: any cardiometabolic risk factor justifies MASLD screening in overweight adults, and MASLD independently worsens sepsis, bleeding, and other outcomes in hospitalized Crohn's disease patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07809477 |
Integrated Diabetes and Oral Health Care in Oman |
NOT_YET_RECRUITING | NA |
| NCT07800468 |
Efficacy of Topical Lidocaine Gel vs. Oral Duloxetine for Painful Diabetic Peripheral Neuropathy |
NOT_YET_RECRUITING | PHASE4 |
| NCT07797335 |
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications |
RECRUITING | PHASE3 |
| NCT07796204 |
Ability of Almonds to Improve Nutrition During GLP-1 Treatment |
NOT_YET_RECRUITING | NA |
| NCT07790081 |
Integrating Educational Videos Into Skills-Based Nutrition Programs to Reduce Type 2 Diabetes Risk in Peel |
RECRUITING | NA |
| NCT07785440 |
Development and Pilot Implementation of a Shared Decision-Making Intervention for Type 2 Diabetes Using the Ottawa Framework |
NOT_YET_RECRUITING | NA |
| NCT07783893 |
E-Health Literacy Intervention for Bangladeshi Migrants With Type 2 Diabetes in Italy |
ACTIVE_NOT_RECRUITING | |
| NCT07778719 |
Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD |
NOT_YET_RECRUITING | NA |
| NCT07778524 |
Alpelisib Challenge Test (ACT) |
RECRUITING | PHASE1 |
| NCT07778121 |
Screening for Obstructive Sleep Apnea in High-risk Patients in a Danish Rural Population: A Pilot Feasibility Study |
COMPLETED | NA |
